Pharmacy and Medical Practice Valuation: A Complete Guide for Australian Healthcare Owners

Introduction

Healthcare businesses occupy a unique position in Australian business valuation. They generate steady, often counter-cyclical revenue. They benefit from government underwriting through Medicare, the Pharmaceutical Benefits Scheme, and the Community Pharmacy Agreement. And they're subject to regulatory frameworks that limit competition and define who can own them.

This combination of stability and regulation means healthcare valuations follow different rules from standard SME valuations. A pharmacy isn't valued like a cafe, and a GP practice isn't valued like a trades business, even if they have similar earnings.

This guide covers the specific methodologies for valuing pharmacies and medical practices in Australia, so you understand what drives value, what adjustments are standard, and what buyers and sellers should expect in 2026.

Part 1: Pharmacy Valuation

The Regulatory Foundation

Australian pharmacies operate under the Eighth Community Pharmacy Agreement (8CPA), which runs from 2025 to 2030. This agreement between the Pharmacy Guild and the federal government sets:

• Dispensing fees - The government-set fee pharmacies receive for each PBS prescription
• Wholesale mark-ups - Permitted margins on the cost price of medicines
• Administrative loadings - Additional payments for regional pharmacies, after-hours service, and dose administration aids
• Location rules - Restrictions on where new pharmacies can open (based on population thresholds)

These rules mean pharmacy profitability is partially underwritten by government policy. A well-located pharmacy with a high prescription volume has a revenue floor that most businesses don't.

Valuation Methodologies

1. EBITDA Multiple Method (Most Common)

Community pharmacies typically trade at 4x to 6x adjusted EBITDA in 2026. The specific multiple depends on:

2. Asset-Based Approach

Pharmacy valuations often split the purchase price into components for CGT purposes:

• Goodwill - The going-concern value and location advantage
• PBS approval - The government licence to dispense PBS scripts (valued separately)
• Fixtures and fittings - Shop fit-out, shelving, computers
• Freehold property - If the pharmacy owns its premises

The PBS approval alone can be worth $200K-$500K depending on prescription volume. This is a regulated asset that cannot be easily replicated, giving it intrinsic value beyond the earnings-based calculation.

3. Turnover Multiple (Rule of Thumb)

Industry rule of thumb: 35-50% of annual turnover. A pharmacy turning over $3M would be worth $1.05M to $1.5M under this approach. This is less precise than EBITDA but provides a quick sanity check.

Adjustments Specific to Pharmacy

Standard EBITDA adjustments apply (excess owner salary, one-off items-see our EBITDA Adjustments Guide), plus pharmacy-specific items:

• Proprietor pharmacist salary - Many pharmacy owners pay themselves a below-market wage and take the balance as dividends or distributions. The valuer will normalise to a market pharmacist salary ($120K-$180K depending on location and role).
• Discounts and rebates - Pharmacies receive rebates from wholesalers and manufacturers. These should be normalised to a sustainable level.
• Prepaid scripts - Some pharmacies have arrangements where regular customers prepay for medications. This creates a liability that should be reflected.

Part 2: Medical Practice Valuation

The Regulatory Framework

Medical practices operate under different rules from pharmacies:

• Corporate ownership is restricted - A medical practice must be owned or controlled by registered medical practitioners (Health Insurance Act 1973). Corporate entities can own the assets (building, equipment) but not the practice itself.
• AHPRA registration - The practice must meet AHPRA standards for accreditation. Loss of accreditation kills the practice's value.
• Medicare provider numbers - Each doctor requires their own Medicare provider number. These cannot be transferred with the practice sale.

Valuation Methodologies

1. EBITDA Multiple Method

Medical practices typically trade at 3x to 5x adjusted EBITDA. The range is lower than pharmacy because competition is less regulated. A new GP can open a practice in any suburb without a government licence.

2. Patient List Valuation

In the UK, GP patient lists are routinely valued. In Australia, this is less common but still used, particularly when the sale involves a retiring doctor's patient base being absorbed into an existing practice.

Patient list valuations work on a per patient basis:

• Active patient (seen in last 12 months): $200-$400 per patient
• Registered patient (seen in last 24 months): $100-$200 per patient
• Inactive patient (not seen in 24+ months): nominal value only

A practice with 5,000 active patients would have a patient list value of $1M to $2M under this approach. However, this is typically cross-checked against the earnings multiple to avoid double-counting.

3. Service Concession Model

For practices where doctors are independent contractors (not employees), the value is based on the service concession fee. The practice charges doctors a percentage of billings (typically 30-40%) for rooms, nursing support, and administration.

For a practice with $4M in total billings and six GPs on 65% splits:

• Practice revenue: 35% x $4M = $1.4M
• Practice costs: $900K (rent, nurses, reception, software)
• Practice EBITDA: $500K

Multiple of 4x gives a practice value of $2M. This is the most common approach for corporate-style medical centres with contractor doctors.

Adjustments Specific to Medical Practices

• Locum costs - If the practice relies heavily on locums, the cost premium over permanent doctors should be noted but is rarely adjusted (it's an ongoing cost, not one-off).
• Doctor turnover - A practice losing a doctor needs the lost revenue stripped from the EBITDA calculation. The valuation should be based on the post-departure earnings capacity.
• Accreditation costs - These are ongoing. No adjustment.
• After-hours and on-call - If the practice collects after-hours fees, assess whether these continue post-sale.

Real Market Data: 2026

Pharmacy Market

As of early 2026, the pharmacy M&A market in Australia shows:

• Vendor expectations have risen post-COVID, with pharmacy profits boosted by higher prescription volumes and Front-of-Shop sales
• Buyer demand remains strong from the major banner groups (Chemist Warehouse, Priceline, TerryWhite Chemmart, Amcal) and independent owner-pharmacists
• Multiples have compressed slightly from the highs of early 2024, settling around 4.5x-5.5x for a standard metropolitan pharmacy
• Regional pharmacies attract lower multiples (3.5x-4.5x) but are harder to finance

Medical Practice Market

• GP practice sales remain steady with 3.5x-5x EBITDA being standard
• Corporate buyers (Australian Clinical Labs, Sonic Healthcare, Healius) are active but selective, targeting practices with $1M+ EBITDA
• Private billing practices command premium multiples over bulk-billing
• Telehealth has permanently expanded the addressable patient base but also introduced competition from purely online practices

Conclusion

Pharmacy and medical practice valuation in Australia requires understanding both standard valuation methodology and the specific regulatory environment. The Community Pharmacy Agreement, AHPRA regulations, and Medicare rules all affect what a healthcare business is worth.

Key takeaways:

• Pharmacies trade at 4x-6x EBITDA, with the PBS approval adding significant asset value
• Medical practices trade at 3x-5x EBITDA, with patient list value providing a secondary check
• Regulatory restrictions on ownership and competition create a moat that supports multiples above standard SMEs
• Always work with a valuer who has specific healthcare experience-A general business valuer may miss pharmacy-specific adjustments

Frequently Asked Questions

What is a pharmacy worth in Australia in 2026?

A standard community pharmacy typically trades at 4x to 6x adjusted EBITDA, plus the value of PBS approvals and freehold property if owned. For a pharmacy doing $3M in turnover with $350K adjusted EBITDA, expect a range of $1.4M to $2.1M excluding property.

Can I value a medical practice based on patient numbers alone?

Patient numbers are an input, not a valuation metric. What matters is billings per patient, the mix of private versus bulk-billed consultations, and the sustainability of the patient base. A practice with 5,000 active patients billing $250 per visit is worth far more than one with 10,000 patients billing $80.

How does the Community Pharmacy Agreement affect valuation?

The 8CPA sets dispensing fees, wholesale mark-ups, and PBS remuneration for 2025-2030. Any change in these terms directly impacts pharmacy profitability and therefore valuation multiples.

Do I need AHPRA approval to buy a medical practice?

Yes. The purchaser must be a registered medical practitioner or entity controlled by one. Corporate structures can hold practice assets but the medical business itself must be owned by a doctor under the Health Insurance Act.

How is pharmacy goodwill different from other business goodwill?

Pharmacy goodwill is heavily regulated. The location, PBS approval, and relationship with the single approved wholesaler all factor in. Unlike a cafe or trades business, you cannot simply open a competing pharmacy next door because of location restrictions under the 8CPA.